39880-85-8

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
N-(3-aminophenyl)-2-thiophenecarboxamide(SALTDATA: FREE) is used as a research compound for its anti-inflammatory and anti-cancer activities. It is valued for its potential to contribute to the development of new therapeutic agents.
Used in Anti-inflammatory Applications:
In the medical field, N-(3-aminophenyl)-2-thiophenecarboxamide(SALTDATA: FREE) is used as an anti-inflammatory agent, leveraging its capacity to modulate inflammatory responses and alleviate symptoms associated with inflammation.
Used in Anti-cancer Applications:
N-(3-aminophenyl)-2-thiophenecarboxamide(SALTDATA: FREE) is employed as an anti-cancer agent, being investigated for its ability to target and inhibit the growth of cancer cells, offering a potential therapeutic strategy for various types of cancer.
Used in Neurological Disorder Treatment:
N-(3-aminophenyl)-2-thiophenecarboxamide(SALTDATA: FREE) is also being explored as a potential treatment for neurological disorders, indicating its broad spectrum of applications within the healthcare sector.
Used in Organic Synthesis:
In the chemical industry, N-(3-aminophenyl)-2-thiophenecarboxamide(SALTDATA: FREE) serves as a building block in organic synthesis, contributing to the creation of new drug candidates and advancing the discovery of novel therapeutic agents.
Overall, N-(3-aminophenyl)-2-thiophenecarboxamide(SALTDATA: FREE) holds significant promise in the realm of medicinal chemistry and drug discovery, with applications spanning from direct therapeutic uses to foundational roles in the synthesis of innovative pharmaceuticals.

InChI:InChI=1/C11H10N2OS/c12-8-3-1-4-9(7-8)13-11(14)10-5-2-6-15-10/h1-7H,12H2,(H,13,14)

Upstream product

• 5271-67-0 2-Thiophenecarbonyl chloride 
• 527-72-0 2-thiophenylcarboxylic acid 
• 99-09-2 3-nitro-aniline 
• 39880-87-0 N-(3-nitrophenyl)thiophene-2-carboxamide 

Downstream Products

• 1192927-91-5 3,4,5-trimethoxy-N-(3-(2-thienylcarboxamido)phenylcarbamothioyl)benzamide 
• 352672-23-2 C₁₈H₁₄N₂O₂S 

Relevant academic research and scientific papers

Design, synthesis, in-silico studies and biological screening of quinazolinone analogues as potential antibacterial agents against MRSA

Type or The emergence of resistance to antibiotic has developed a complicated situation in the treatment of bacterial infections. Considering the antimicrobial resistance phenomenon as one of the greatest challenge of medicinal chemists for search of better anti-bacterial agents, which have potential narrow spectrum activity with low development of resistance potential and low toxicity to host. Cross-linking of peptidoglycan is a key step catalyze by Penicillin binding protein (PBP) to maintain integrity of cell wall in bacterial cell. However, these Penicillin binding protein (PBP) has developed resistance in methicillin-resistant Staphylococcus aureus (MRSA) due to acquisition of additional PBP2a. Various Quinazolinone analogues are reported in literature as potential anti-bacterial agents against MRSA. In present study new quinazolinone analogues has been designed, guided by molecular docking, In-silico and MM-GBSA study. Newly designed molecules have been synthesized by medicinal chemistry route and their characterization was done by using IR, NMR, & HR-MS techniques. Biological evaluation of synthesized compounds has been done on wild type Gram-negative (Escherichia coli), Gram-positive (Staphylococcus aureus) and resistant MRSA bacterial strains using Streptomycin, Kanamycin and Linezolid as standard drugs respectively. The in vitro evaluation results have shown that compound 5f is active with MIC value 15.625 μg/mL against S. aureus and with MIC value 31.25 μg/mL against MRSA.

Potent and selective inhibitors of the TASK-1 potassium channel through chemical optimization of a bis-amide scaffold

TASK-1 is a two-pore domain potassium channel that is important to modulating cell excitability, most notably in the context of neuronal pathways. In order to leverage TASK-1 for therapeutic benefit, its physiological role needs better characterization; however, designing selective inhibitors that avoid the closely related TASK-3 channel has been challenging. In this study, a series of bis-amide derived compounds were found to demonstrate improved TASK-1 selectivity over TASK-3 compared to reported inhibitors. Optimization of a marginally selective hit led to analog 35 which displays a TASK-1 IC 50 = 16 nM with 62-fold selectivity over TASK-3 in an orthogonal electrophysiology assay.

Acylthiourea, acylurea, and acylguanidine derivatives with potent Hedgehog inhibiting activity

The Smoothened (Smo) receptor is the major transducer of the Hedgehog (Hh) signaling pathway. On the basis of the structure of the acylthiourea Smo antagonist (MRT-10), a number of different series of analogous compounds were prepared by ligand-based structural optimization. The acylthioureas, originally identified as actives, were converted into the corresponding acylureas or acylguanidines. In each series, similar structural trends delivered potent compounds with IC50 values in the nanomolar range with respect to the inhibition of the Hh signaling pathway in various cell-based assays and of BODIPY-cyclopamine binding to human Smo. The similarity of their biological activities, in spite of discrete structural differences, may reveal the existence of hydrogen-bonding interactions between the ligands and the receptor pocket. Biological potency of compounds 61, 72, and 86 (MRT-83) were comparable to those of the clinical candidate GDC-0449. These findings suggest that these original molecules will help delineate Smo and Hh functions and can be developed as potential anticancer agents.